Structure of herd immunity to SARS-COV-2 in the Krasnoyarsk region population in the COVID-19 epidemic

Попова, А. Ю.; Ежлова, Е. Б.; Мельникова, А. А.; Смирнов, В. С.; Лялина, Л. В.; Горяев, Д В; Ходов, Д. А.; Чепижко, Т. Г.; Rusin, Monika; Kuznetsova, N. N.; Безручко, Е. Ю.; Кочергина, А. С.; Каримов, В. Р.; Sharova, A. A.; Ветров, В. В.; Тотолян, Арег А.

doi:10.29413/abs.2021-6.3.23

Cited by 4 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a practical point of view, epidemiological analysis of the state of collective immunity using serological methods (for determining the prevalence of SARS-CoV-2 Abs) and other epidemiological analysis approaches are more appropriate [ 12 , 13 ]. This article continues our previous publications analyzing SARS-CoV-2 Ab seroprevalence, such as our cross-sectional study of herd immunity in the St. Petersburg population [ 14 ] conducted in the early period of COVID-19 incidence (13–20 June 2020), as well as longitudinal seromonitoring of the population in 26 regions of Russia [ 15 , 16 , 17 , 18 , 19 , 20 ]. Features of seroprevalence in Belarus and Kyrgyzstan (2020–21) were also analyzed [ 21 , 22 ].…”

Section: Introductionsupporting

confidence: 65%

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

Смирнов

Lyalina

Миличкина

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

Introduction. Since the detection of the first COVID-19 patient, 2 years have passed, during which more than 287,862,000 people have fallen ill globally, of which about 1.9% died. The implementation of SARS-CoV-2 control programs required efforts from almost all countries. An important direction in the fight against COVID-19 has been the formation of herd immunity, the main tool for managing the pandemic. Study goal. The aim of the study was to assess the seroprevalence of antibodies (Abs) to SARS-CoV-2 nucleocapsid (Nc) and receptor binding domain (RBD) in the St. Petersburg population during the COVID-19 pandemic. Materials and methods. A longitudinal cohort randomized monitoring study of Ab seroprevalence (SARS-CoV-2 Nc, RBD) was organized and conducted according to a unified methodology developed by Rospotrebnadzor with the participation of the St. Petersburg Pasteur Institute. For this purpose, a cohort was formed of 1000 volunteers who participated in all five stages of seromonitoring. The cohort was divided into seven age groups: 1–17; 18–29; 30–39; 40–49; 50–59; 60–69; 70; and older (70+) years. Seropositivity levels (Nc, RBD) were assessed by quantitative and qualitative enzyme immunoassays. During the second year of monitoring, some volunteers were vaccinated with the GamCOVIDVac (84%) or EpiVacCorona (11.6%) vaccines approved in Russia. Statistical processing was carried out using Excel 2010. Confidence intervals for shares and percentages (95% CI) were calculated using the method of A. Wald and J. Wolfowitz with adjustment (A. Agresti, B.A. Coull). The statistical significance of differences was calculated by z-test, using the appropriate online calculator (p < 0.05) unless indicated. Results. There was a trend toward an increase in Nc seropositivity in stages 1–3 of seromonitoring, with a decrease in stages 4–5 among children and adults. The share of RBD seropositive steadily increased during all five stages of seromonitoring. The most frequent finding was low anti-RBD Abs levels (22.6–220 BAU/mL). High Ab levels were recorded statistically significantly less frequently. Asymptomatic forms were observed in 84–88% of SARS-CoV-2 seropositive volunteers. By the fifth stage of monitoring, this indicator significantly decreased to 69.8% (95% CI: 66.1–73.4). The monitoring revealed a statistically significant increase in anti-RBD Abs alongside a statistically significant decrease in the proportion of Nc seropositives. This dynamic was especially characteristic of persons vaccinated with GamCOVIDVac. Conclusion. Prior to the use of specific vaccines, a seroprevalence of anti-Nc Abs was noted. After the introduction of the GamCOVIDVac vaccine in adults, a decrease in the level of anti-Nc Abs was noted due to an increase in the proportion of RBD seropositive persons.

show abstract

Section: Introductionsupporting

confidence: 65%

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

Смирнов

Lyalina

Миличкина

et al. 2022

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this study, individuals were classi ed as asymptomatic who, in addition to Abs to Nag, did not show any symptoms of COVID-19. According to our data, their share can reach 90% or more of all seropositive individuals [28,30,40]. This study identi ed 3647 asymptomatic cases in 4609 seropositive volunteers (79.1% (95% CI 77.9-80.3)) (Table 7).…”

Section: Assessment Of the Proportions Of Asymptomatic Covid-19 Among...mentioning

confidence: 73%

SARS-CoV-2 herd immunity of the Kyrgyz population in 2021

Popova

Kasymov²,

Smolenski

et al. 2022

Med Microbiol Immunol

Self Cite

View full text Add to dashboard Cite

Background. In the ght against coronavirus infection, an important direction is control of herd immunity to the pathogen. SARS-CoV-2 herd immunity is formed naturally as a result of manifest or asymptomatic infection, or arti cially as a result of vaccination Aim: To assess the SARS-CoV-2 herd immunity status of the Kyrgyz population. Materials and methods. A cross-sectional, randomized study of SARS-CoV-2 herd immunity was carried out according to a program developed by Rospotrebnadzor, with the participation of the Saint Petersburg Pasteur Institute, taking into account WHO recommendations. In all study stages cloud service (internet) technologies were used. The ethics committees of the Preventive Medicine Association (Kyrgyzstan) and the Saint Petersburg Pasteur Institute (Russia) approved the study. A total of 9,471 volunteers were selected, representing 0.15% (95% CI 0.14-0.15) of the total population. They were randomized according to age and region. Antibodies (Abs) to the nucleocapsid antigen (Nag) were determined by enzyme-linked immunosorbent assay (ELISA) of volunteer blood plasma. For vaccinated individuals, Abs to the SARS-CoV-2 receptor-binding domain antigen (RBDag) were determined. Statistical processing of the results was carried out using Excel 2010 and other programs. Differences were designated as statistically signi cant at p<0.05.Results. The seroprevalence of the general population was 48.7% (95% CI 47.7-49.7), with a maximum in the group of '60-69 year old' (59.2% (56.6-61.7)) and a minimum in the group '1-17 y.o.' (32.7% (95 CI 29.4-36.1)). The largest proportion seropositive was found in the Chui region (51.3% (95% CI 47.9-54.8)).The lowest was in Osh city )). The maximum seropositivity was detected among healthcare workers (57.1% (95% CI 55.4-58.8); the minimum was noted among artists (38.6% (95% CI 26.0-52.4)). Asymptomatic SARS-CoV-2 positivity was 79.1% (96% CI 77.9-80.3). Vaccination with Sputnik V, EpiVacCorona, or Sinopharm formed comparable levels of immunity.Conclusions. The herd immunity to SARS-CoV-2 Nag is 48.75% (95% CI 47.7-49.7), and the overall immunity (Nag + RBDag) is 57%.

show abstract

“…From a practical point of view, epidemiological analysis of the state of collective immunity using serological methods (for determining the prevalence of SARS-CoV-2 Abs) and other epidemiological analysis approaches are more appropriate [12,13]. This article continues our previous publications analyzing SARS-CoV-2 Ab seroprevalence, such as our cross-sectional study of herd immunity in the St. Petersburg population [14] conducted in the early period of COVID-19 incidence (13-20/06/2020), as well as longitudinal seromonitoring of the population in 26 regions of Russia [15][16][17][18][19][20]. Features of seroprevalence in Belarus and Kyrgyzstan (2020-21) were also analyzed [21,22].…”

Section: Introductionmentioning

confidence: 63%

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

Смирнов¹,

Lyalina²,

Milichkina³

et al. 2022

Preprint

View full text Add to dashboard Cite

Since the detection of the first COVID-19 patient, 2 years have passed, during which more than 287,862,000 people fell ill globally, of which about 1.9% died. Implementation of SARS-CoV-2 control programs required efforts from almost all countries. An important direction in the fight against COVID-19 was the formation of herd immunity, the main tool for managing the pandemic. Study goal: to assess the seroprevalence of antibodies (Abs) to SARS-CoV-2 nucleocapsid (Nc) and receptor binding domain (RBD) in the St. Petersburg population during the COVID-19 pandemic. Materials and methods. A longitudinal cohort randomized monitoring study of Ab seroprevalence (SARS-CoV-2 Nc, RBD) was organized and conducted according to a unified methodology developed by Rospotrebnadzor with the participation of the St. Petersburg Pasteur Institute. For this purpose, a cohort of 1000 volunteers was formed who participated in all five stages of seromonitoring. The cohort was divided into 7 age groups: 1-17; 18-29; 30-39; 40-49; 50-59; 60-69; 70; and older (70+) years. Seropositivity levels (Nc, RBD) were assessed by quantitative and qualitative enzyme immunoassays. During the 2nd year of monitoring, some volunteers were vaccinated with the GamCOVIDVac (84%) or EpiVacCorona (11.6%) vaccines approved in Russia. Statistical processing was carried out using the Excel 2010 software package. Confidence intervals for shares and percentages (95% CI) were calculated using the method of A. Wald and J. Wolfowitz with adjustment (A. Agresti, B.A. Coull). The statistical significance of differences was calculated by z-test, using the appropriate online calculator (p<0.05), unless indicated. Results. There was a trend towards: an increase in Nc seropositivity in stages 1-3 of seromonitoring, with a decrease in stages 4-5 among children and adults. The share of RBD seropositive steadily increased during all 5 stages of seromonitoring. The most frequently found were low anti-RBD Abs levels (22.6-220 BAU/ml). High Ab levels were recorded statistically significantly less frequently. Asymptomatic forms were observed in 84-88% of SARS-CoV-2 seropositive volunteers. By the 5th stage of monitoring, this indicator significantly decreased to 69.8% (95% CI: 66.1-73.4). The monitoring revealed a statistically significant increase in anti-RBD Abs, alongside a statistically significant decrease in the proportion of Nc seropositive. This dynamic was especially characteristic of persons vaccinated with GamCOVIDVac. Conclusion. Prior to the use of specific vaccines, a seroprevalence of anti-Nc Abs was noted. After the introduction of the GamCOVIDVac vaccine in adults, a decrease in the level of anti-Nc Abs was noted due to an increase in the proportion of RBD seropositive persons.

show abstract

Structure of herd immunity to SARS-COV-2 in the Krasnoyarsk region population in the COVID-19 epidemic

Cited by 4 publications

References 22 publications

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

SARS-CoV-2 herd immunity of the Kyrgyz population in 2021

Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population

Contact Info

Product

Resources

About